Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1924 1
1938 1
1939 5
1940 1
1941 1
1942 1
1946 2
1947 3
1948 5
1949 2
1950 12
1951 13
1952 35
1953 21
1954 9
1955 12
1956 9
1957 22
1958 17
1959 21
1960 11
1961 13
1962 28
1963 48
1964 34
1965 42
1966 43
1967 40
1968 32
1969 40
1970 41
1971 40
1972 55
1973 60
1974 64
1975 62
1976 94
1977 84
1978 89
1979 125
1980 140
1981 169
1982 222
1983 209
1984 259
1985 294
1986 311
1987 384
1988 394
1989 428
1990 523
1991 574
1992 633
1993 752
1994 826
1995 980
1996 1115
1997 1330
1998 1483
1999 1834
2000 2163
2001 2500
2002 2988
2003 3491
2004 4169
2005 5046
2006 5802
2007 6345
2008 7425
2009 8176
2010 9255
2011 10532
2012 12081
2013 13237
2014 14838
2015 15972
2016 16988
2017 18141
2018 20193
2019 22970
2020 26597
2021 30165
2022 34331
2023 9958
Text availability
Article attribute
Article type
Publication date

Search Results

284,229 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Yu-Tsang
Page 1
Did you mean yu tsung lu (1 results)?
Lutetium-177-PSMA-617: A Vision of the Future.
Chandran E, Figg WD, Madan R. Chandran E, et al. Cancer Biol Ther. 2022 Dec 31;23(1):186-190. doi: 10.1080/15384047.2022.2037985. Cancer Biol Ther. 2022. PMID: 35220877 Free PMC article.
The recent VISION trial is the first to demonstrate a survival benefit of Lutetium-177[(177)Lu]Lu-PSMA-617 in post-chemotherapy mCRPC. This journal club reviews the VISION trial in the context of the earlier TheraP trial of [(177)Lu]Lu-PSMA-617 in mCRP …
The recent VISION trial is the first to demonstrate a survival benefit of Lutetium-177[(177)Lu]Lu-PSMA-617 in post-chemotherap …
[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer.
Hennrich U, Eder M. Hennrich U, et al. Pharmaceuticals (Basel). 2022 Oct 20;15(10):1292. doi: 10.3390/ph15101292. Pharmaceuticals (Basel). 2022. PMID: 36297404 Free PMC article. Review.
In March 2022, [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)) was approved by the FDA for the treatment of prostate cancer patients. ...In numerous clinical trials, the efficacy of [(177)Lu]Lu-PSMA-617 was demonstrated....
In March 2022, [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)) was approved by the FDA for the treatment of prostate cancer patients. ...I …
Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry.
Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP. Schuchardt C, et al. J Nucl Med. 2022 Aug;63(8):1199-1207. doi: 10.2967/jnumed.121.262713. Epub 2021 Dec 9. J Nucl Med. 2022. PMID: 34887335 Free PMC article.
Despite the longer half-life of (177)Lu-PSMA-617, the renal dose was lower for (177)Lu-PSMA-617 than for (177)Lu-PSMA I&T (0.77 vs. 0.92 Gy/GBq, P = 0.0015). ...No nephrotoxicity was observed after either (177)Lu-PSMA I&T or (177)Lu-PSMA …
Despite the longer half-life of (177)Lu-PSMA-617, the renal dose was lower for (177)Lu-PSMA-617 than for (177)Lu-PSMA I …
First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2.
Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, Bal C. Ballal S, et al. Pharmaceuticals (Basel). 2021 Nov 24;14(12):1212. doi: 10.3390/ph14121212. Pharmaceuticals (Basel). 2021. PMID: 34959613 Free PMC article.
The FAPi agents, [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2), were administered in two different groups of patients. ...The first clinical dosimetry study demonstrated significantly higher tumor absorbed doses with [(177)Lu]L
The FAPi agents, [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2), were administered in two differen …
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
Ruigrok EAM, van Vliet N, Dalm SU, de Blois E, van Gent DC, Haeck J, de Ridder C, Stuurman D, Konijnenberg MW, van Weerden WM, de Jong M, Nonnekens J. Ruigrok EAM, et al. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1339-1350. doi: 10.1007/s00259-020-05057-6. Epub 2020 Oct 23. Eur J Nucl Med Mol Imaging. 2021. PMID: 33094433 Free PMC article.
Autoradiography assays on cryosections of human salivary and renal tissues revealed [(177)Lu]Lu-PSMA-617 to have the lowest binding to these healthy organs compared with [(177)Lu]Lu-PSMA-I&T. ...CONCLUSION: [(177)Lu]Lu-PSMA-617 has th …
Autoradiography assays on cryosections of human salivary and renal tissues revealed [(177)Lu]Lu-PSMA-617 to have the lowest bi …
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.
von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, Joensuu T. von Eyben FE, et al. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):496-508. doi: 10.1007/s00259-017-3895-x. Epub 2017 Dec 16. Eur J Nucl Med Mol Imaging. 2018. PMID: 29247284 Free PMC article. Review.
The treatment with (177)Lu-PSMA-617 and (177)Lu-PSMA for imaging and therapy (I&T) had mainly transient adverse effects. ...CONCLUSIONS: As for patients with mCRPC, treatment with (177)Lu-PSMA-617 RTL and (177)Lu-PSMA I&T gave better effects an …
The treatment with (177)Lu-PSMA-617 and (177)Lu-PSMA for imaging and therapy (I&T) had mainly transient adverse effects. . …
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC.
Hänscheid H, Hartrampf PE, Schirbel A, Buck AK, Lapa C. Hänscheid H, et al. Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2566-2572. doi: 10.1007/s00259-020-05177-z. Epub 2021 Jan 15. Eur J Nucl Med Mol Imaging. 2021. PMID: 33452632 Free PMC article.
It was tested in selected patients whether the substance is superior to [(177)Lu]Lu-DOTA-TOC. METHODS: Activity kinetics in organs and tumours after [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC were compared intraindividually in five …
It was tested in selected patients whether the substance is superior to [(177)Lu]Lu-DOTA-TOC. METHODS: Activity kinetics in or …
Lutetium Lu 177 Dotatate.
[No authors listed] [No authors listed] 2020 Aug 17. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2020 Aug 17. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000023 Free Books & Documents. Review.
Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. No information is available on the use of lutetium Lu 177 dotatate during breastfeeding. The ma …
Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroen …
Quality control of [177Lu]Lu-PSMA preparations using HPLC: effect of sample composition and ligand on recovery.
Aalbersberg EA, Cao TT, Geluk-Jonker MM, Hendrikx JJMA. Aalbersberg EA, et al. EJNMMI Radiopharm Chem. 2022 Sep 27;7(1):24. doi: 10.1186/s41181-022-00178-9. EJNMMI Radiopharm Chem. 2022. PMID: 36166155 Free PMC article.
BACKGROUND: [(177)Lu]Lu-PSMA is used for the treatment of metastatic castration-resistant prostate cancer. ...The low recovery of [(177)Lu]Lu-PSMA-617 could not be prevented with addition of unlabeled PSMA-617. ...
BACKGROUND: [(177)Lu]Lu-PSMA is used for the treatment of metastatic castration-resistant prostate cancer. ...The low recovery …
Preclinical Investigations to Explore the Difference between the Diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward Prostate Cancer Therapy.
Borgna F, Deberle LM, Busslinger SD, Tschan VJ, Walde LM, Becker AE, Schibli R, Müller C. Borgna F, et al. Mol Pharm. 2022 Jul 4;19(7):2105-2114. doi: 10.1021/acs.molpharmaceut.1c00994. Epub 2022 May 11. Mol Pharm. 2022. PMID: 35544699
In vivo, [(177)Lu]Lu-SibuDAB was metabolically more stable than [(177)Lu]Lu-RibuDAB with 90 vs 67% intact radioligand detected in the blood at 4 h post injection (p.i.). ...A twofold increased area under the curve (AUC(08d)) of the blood retention was …
In vivo, [(177)Lu]Lu-SibuDAB was metabolically more stable than [(177)Lu]Lu-RibuDAB with 90 vs 67% intact radiol …
284,229 results
You have reached the last available page of results. Please see the User Guide for more information.